BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

489 related articles for article (PubMed ID: 7532767)

  • 1. CD34 expression is associated with major adverse prognostic factors in adult acute lymphoblastic leukemia.
    Thomas X; Archimbaud E; Charrin C; Magaud JP; Fiere D
    Leukemia; 1995 Feb; 9(2):249-53. PubMed ID: 7532767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical relevance of CD10 expression in childhood ALL. The Italian Association for Pediatric Hematology and Oncology (AIEOP).
    Consolini R; Legitimo A; Rondelli R; Guguelmi C; Barisone E; Lippi A; Cantù-Rajnoldi A; Aricò M; Conter V; Cocito MG; Putti MC; Pession A; Masera G; Biondi A; Basso G
    Haematologica; 1998 Nov; 83(11):967-73. PubMed ID: 9864914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. B-lineage acute lymphoblastic leukemia of childhood. An institutional experience.
    Rivera-Luna R; Cardenas-Cardos R; Leal-Leal C; Navarro-Alegría I; Meza-Coria C; Gómez-Martínez R; Vega-Vega L
    Arch Med Res; 1997; 28(2):233-9. PubMed ID: 9204615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of CD10, CD19 and CD34 markers in bone marrow samples of children with precursor B-cell acute lymphoblastic leukemia in clinical and hematological remission.
    Cáp J; Babusíková O; Kaiserová E; Jamárik M
    Neoplasma; 1998; 45(4):231-6. PubMed ID: 9890666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fractionated cyclophosphamide added to the IVAP regimen (idarubicin-vincristine-L-asparaginase-prednisone) could lower the risk of primary refractory disease in T-lineage but not B-lineage acute lymphoblastic leukemia: first results from a phase II clinical study.
    Bassan R; Pogliani E; Lerede T; Fabris P; Rossi G; Morandi S; Casula P; Lambertenghi-Deliliers G; Vespignani M; Izzi T; Coser P; Corneo G; Barbui T
    Haematologica; 1999 Dec; 84(12):1088-93. PubMed ID: 10586210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation between CD34 expression and chromosomal abnormalities but not clinical outcome in acute myeloid leukemia.
    Fruchart C; Lenormand B; Bastard C; Boulet D; Lesesve JF; Callat MP; Stamatoullas A; Monconduit M; Tilly H
    Am J Hematol; 1996 Nov; 53(3):175-80. PubMed ID: 8895688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adult and childhood acute lymphoblastic leukemia: clinico-biological differences based on CD34 antigen expression.
    Cascavilla N; Musto P; D'Arena G; Ladogana S; Matera R; Carotenuto M
    Haematologica; 1997; 82(1):31-7. PubMed ID: 9107079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial.
    Ribera JM; Ortega JJ; Oriol A; Granada I; Hernández-Rivas JM; Parody R; Bethencourt C; Rivas C; Bastida P; del Potro E; González-Valentín ME; Moreno MJ; Besalduch J; Fernández-Calvo J; Tormo M; Arias J; Molinés A; Sanz MA; Maldonado J; Millá F; Feliu E; San Miguel JF;
    Haematologica; 2002 Feb; 87(2):154-66. PubMed ID: 11836166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute myelofibrosis terminating in acute lymphoblastic leukemia: case report and review of the literature.
    Dunphy CH; Kitchen S; Saravia O; Velasquez WS
    Am J Hematol; 1996 Jan; 51(1):85-9. PubMed ID: 8571944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL93 study.
    Takeuchi J; Kyo T; Naito K; Sao H; Takahashi M; Miyawaki S; Kuriyama K; Ohtake S; Yagasaki F; Murakami H; Asou N; Ino T; Okamoto T; Usui N; Nishimura M; Shinagawa K; Fukushima T; Taguchi H; Morii T; Mizuta S; Akiyama H; Nakamura Y; Ohshima T; Ohno R
    Leukemia; 2002 Jul; 16(7):1259-66. PubMed ID: 12094249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811.
    Larson RA; Dodge RK; Burns CP; Lee EJ; Stone RM; Schulman P; Duggan D; Davey FR; Sobol RE; Frankel SR
    Blood; 1995 Apr; 85(8):2025-37. PubMed ID: 7718875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of the PETHEMA ALL-96 trial in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia.
    Sancho JM; Ribera JM; Xicoy B; Morgades M; Oriol A; Tormo M; del Potro E; Debén G; Abella E; Bethencourt C; Ortín X; Brunet S; Ortega-Rivas F; Novo A; López R; Hernández-Rivas JM; Sanz MA; Feliu E;
    Eur J Haematol; 2007 Feb; 78(2):102-10. PubMed ID: 17087744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peroxidase-negative and myelomonocytic antigen-positive acute leukemia.
    Okawa H; Nagasawa M; Morio T; Takase K; Tanaka K; Yata J; Dan K; Nomura T; Sakamaki H; Onozawa Y
    Int J Hematol; 1992 Apr; 55(2):165-71. PubMed ID: 1324747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of myeloid antigens by blast cells in acute lymphoblastic leukemia of adults. The Southwest Oncology Group experience.
    Boldt DH; Kopecky KJ; Head D; Gehly G; Radich JP; Appelbaum FR
    Leukemia; 1994 Dec; 8(12):2118-26. PubMed ID: 7807999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current results of studies of immunophenotype-, age- and leukocyte-based therapy for children with acute lymphoblastic leukemia. The Pediatric Oncology Group.
    Crist W; Shuster J; Look T; Borowitz M; Behm F; Bowman P; Frankel L; Pullen J; Krance R; Steuber P
    Leukemia; 1992; 6 Suppl 2():162-6. PubMed ID: 1578922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymphoblastic lymphoma.
    Cortelazzo S; Ponzoni M; Ferreri AJ; Hoelzer D
    Crit Rev Oncol Hematol; 2011 Sep; 79(3):330-43. PubMed ID: 21273093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistence of peripheral blood and bone marrow blasts during remission induction in adult acute lymphoblastic leukemia confers a poor prognosis depending on treatment intensity.
    Cortes J; Fayad L; O'Brien S; Keating M; Kantarjian H
    Clin Cancer Res; 1999 Sep; 5(9):2491-7. PubMed ID: 10499624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of early anthracycline dose-intensity according to expression of Philadelphia chromosome/BCR-ABL rearrangements in B-precursor adult acute lymphoblastic leukemia.
    Bassan R; Rohatiner AZ; Lerede T; Di Bona E; Rambaldi A; Pogliani E; Rossi G; Fabris P; Morandi S; Casula P; Carter M; Lambertenghi-Deliliers G; Lister TA; Barbui T
    Hematol J; 2000; 1(4):226-34. PubMed ID: 11920195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute leukemia coexpressing myeloid, B- and T-lineage associated markers: multiparameter analysis of criteria defining lineage commitment and maturational stage in a case of undifferentiated leukemia.
    Meckenstock G; Heyll A; Schneider EM; Hildebrandt B; Runde V; Aul C; Bartram CR; Ludwig WD; Schneider W
    Leukemia; 1995 Feb; 9(2):260-4. PubMed ID: 7869761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Additional chromosomal abnormalities and their prognostic significance in adult Philadelphia-positive acute lymphoblastic leukemia: with or without imatinib in chemotherapy.
    Li Y; Qiu L; Zou D; Zhao Y; Mi Y; Wang J
    Ann Hematol; 2009 Nov; 88(11):1069-77. PubMed ID: 19277658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.